Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 27, 2022
Daily News
September 27, 2022
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- MHLW’s Healthcare DX Promotion Team Holds 1st Meeting, Sets Up 2 Task Forces
September 27, 2022
- Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
- Keytruda Gets Label Update to Add Adjuvant Data for Melanoma
September 27, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…